Private label famotidine
This article was originally published in The Tan Sheet
Executive Summary
Cheminor Drugs receives tentative approval from FDA Dec. 13 for OTC famotidine 10 mg tablets (ANDA 75-758). Reference drug is J&J/Merck's Pepcid AC, which recently was granted additional six months of exclusivity based on pediatric data submitted by firm, postponing market entry of generic versions of H2 antagonist until April 15. Both Teva Pharmaceuticals and Danbury Pharmacal also have tentative approvals; Perrigo, PFI, Leiner and Zenith Goldline intend to offer generic famotidine in 2001 (1"The Tan Sheet" Nov. 27, p. 11)
You may also be interested in...
Generic Famotidine Launch Delayed By Pepcid AC Pediatric Exclusivity
Private label famotidine 10 mg products will not launch until after April 15 due to FDA's Nov. 21 decision to grant J&J/Merck an additional six months of marketing exclusivity for Pepcid AC after reviewing pediatric data submitted by the firm.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands